Varenicline (marketed as Chantix) Information
Varenacline (marketed as Chantix) is a medication used as an aid to smoking cessation treatment.
To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.
Related Information
- FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings
- FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking
- FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events
- FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events
- FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease
- FDA Drug Safety Podcast: Chantix may increase cardiovascular risk in certain patients
- Chantix: Quarterwatch Article
- Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban
- Podcast: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban
- Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
- Public Health Advisory: Important Information on Chantix (varenicline)
- Information for Healthcare Professionals: Varenicline (marketed as Chantix)
- Public Health Advisory: Important Information on Chantix (varenicline)
- FDA Issues Public Health Advisory on Chantix
- Early Communication About an Ongoing Safety Review of Varenicline (marketed as Chantix)